Lenalidomide in the treatment of multiple myeloma: a review (Q34775515)

4 August 2017

1 reference

title

Lenalidomide in the treatment of multiple myeloma: a review (English)

1 reference

4 August 2017

1 reference

X Armoiry

1

1 reference

PubMed ID

18452408

4 August 2017

G Aulagner

series ordinal

2

1 reference

PubMed ID

18452408

4 August 2017

T Facon

series ordinal

3

1 reference

4 August 2017

1 June 2008

1 reference

Journal of Clinical Pharmacy and Therapeutics

4 August 2017

1 reference

4 August 2017

33

1 reference

4 August 2017

3

1 reference

4 August 2017

219-226

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

4 August 2017

1 reference

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

21 January 2018

Immunomodulatory drugs.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

21 January 2018

New drugs for myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2008.00920.X

10.1111/J.1365-2710.2008.00920.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

18452408